|国家科技期刊平台
首页|期刊导航|医学信息|立体定向放射治疗联合深部热疗在中晚期肝癌中的临床应用

立体定向放射治疗联合深部热疗在中晚期肝癌中的临床应用OA

Clinical Application of Stereotactic Body Radiotherapy Combined with Deep Hyperthermia in Advanced Liver Cancer

中文摘要英文摘要

目的 探讨立体定向放射治疗联合深部热疗对中晚期肝癌的疗效及毒副反应.方法 收集2020年6月-2022年2月广州中医药大学金沙洲医院收治的中晚期肝癌患者33例,采用立体定向放射治疗联合深部热疗治疗,分析患者临床疗效、生存情况及毒副反应.结果 全组患者中有32例患者可评估疗效,其中获CR 1例(3.13%),PR 24例(75.00%)、SD 4例(12.50%)、PD 3例(9.38%),RR为78.13%,DCR为90.63%.32例患者总生存时间为5~26个月,中位总生存时间为12.6个月,1年的总生存率为81.25%.常见的毒副反应为血液性毒性和胃肠道反应,大部分为轻度到中度,无治疗相关性死亡.结论 立体定向放射治疗联合深部热疗在中晚期肝癌中的疗效确切,且安全性较高,有望弥补单一放射治疗所致的不足.

Objective To investigate the efficacy and toxicity of stereotactic body radiotherapy combined with deep hyperthermia in the treatment of advanced liver cancer.Methods A total of 33 patients with advanced liver cancer admitted to Jinshazhou Hospital of Guangzhou University of Traditional Chinese Medicine from June 2020 to February 2022 were collected and treated with stereotactic body radiotherapy combined with deep hyperthermia.The clinical efficacy,survival and side effects of the patients were analyzed.Results There were 32 patients who could be evaluated for efficacy,including 1 case(3.13%)of CR,24 cases(75.00%)of PR,4 cases(12.50%)of SD and 3 cases(9.38%)of PD,with RR of 78.13%and DCR of 90.63%.The overall survival time of 32 patients was 5-26 months,the median overall survival time was 12.6 months,and the 1-year overall survival rate was 81.25%.The common side effects were hematological toxicity and gastrointestinal reactions,most of which were mild to moderate,and there was no treatment-related death.Conclusion Stereotactic body radiotherapy combined with deep hyperthermia is effective and safe in the treatment of advanced liver cancer,which is expected to make up for the deficiency caused by single radiotherapy.

徐振华;向世强

武汉科技大学医学院公共卫生学院,湖北 武汉 430065

临床医学

中晚期肝癌立体定向放射治疗深部热疗

Advanced liver cancerStereotactic body radiotherapyDeep hyperthermia

《医学信息》 2024 (011)

112-115 / 4

10.3969/j.issn.1006-1959.2024.11.021

评论